Evidence map›Paper›PMID 29305422›Full record

ArticleThe Journal of biological chemistry2018

Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.

Lina Al-Akra, Dong-Hun Bae, Sumit Sahni, Michael L H Huang, Kyung Chan Park, Darius J R Lane, Patric J Jansson, Des R Richardson

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 51 citations in OpenAlex.

  1. Lysosome as a Chemical Reactor.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Unveiling the mechanisms and challenges of cancer drug resistance.Cell communication and signaling : CCS · 2024
    Review
  6. Review
  7. Review
  8. Lysosomes as a Target of Anticancer Therapy.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lina Al-AkraFrom the Molecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales 2006, Australia.
Dong-Hun BaeFrom the Molecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales 2006, Australia.
Sumit SahniFrom the Molecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales 2006, Australia.
Michael L H HuangFrom the Molecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales 2006, Australia.
Kyung Chan ParkFrom the Molecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales 2006, Australia.
Darius J R LaneFrom the Molecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales 2006, Australia.
Patric J JanssonFrom the Molecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales 2006, Australia patric.jansson@sydney.edu.au.
Des R RichardsonFrom the Molecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales 2006, Australia d.richardson@med.usyd.edu.au.
Robert Bosch (Australia) · AUUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance (MDR) is a major obstacle in cancer treatment due to the ability of tumor cells to efflux chemotherapeutics via drug transporters (

Indexed as

Models, BiologicalAcridinesAntineoplastic AgentsApoptosisATP Binding Cassette Transporter, Subfamily BBiological TransportCell HypoxiaCell Line, TumorCell ProliferationDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansHydrogen PeroxideHypoxia-Inducible Factor 1, alpha SubunitABCB1 protein, humanAcridinesAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily Bdi-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazoneDoxorubicinElacridarHydrogen PeroxideHypoxia-Inducible Factor 1, alpha SubunitNeoplasm ProteinsTetrahydroisoquinolinesThiosemicarbazonesABCB1drug deliverydrug resistancedrug transportlysosomeP-glycoproteintumor micro-environmenttumor micro-environmental stress

Identifiers

PMID29305422
PMCPMC5846167
OpenAlexW2781787692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.